{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-142114","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2026-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.875961+00:00","generated_at":"2026-05-15T07:38:37.090293+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Climb Bio SVP Finance to depart April 30; CFO adds principal accounting officer role","bullets":["Cindy Driscoll, SVP Finance and principal accounting officer, to separate from Climb Bio effective April 30, 2026, by mutual agreement.","CFO Susan Altschuller will also serve as principal accounting officer starting on the Separation Date.","Altschuller has been CFO since Oct 2025; prior CFO roles at Dragonfly Therapeutics, Cerevel Therapeutics, and ImmunoGen."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-142114","json":"https://secwatch.observer/filing/0001193125-26-142114.json","markdown":"https://secwatch.observer/filing/0001193125-26-142114.md","text":"https://secwatch.observer/filing/0001193125-26-142114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526142114/0001193125-26-142114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526142114/d59877d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:38:37.090293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}